Neurocrine Biosciences NBIX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 393.6%+0.2pp | 393.4%+1.4pp | 392%-2.3pp | 394.3%-1.0pp | |
| Operating margin | 82.4%-16.4pp | 98.8%+56.8pp | 42%— | —— | |
| Net margin | 59.2%-7.1pp | 66.4%+27.9pp | 38.5%+15.4pp | 23.1%-101pp | |
| Returns | |||||
| Return on equity | 57.2%-7.1pp | 64.2%+25.8pp | 38.4%+16.3pp | 22.1%-104pp | |
| Return on invested capital | 51.5%-17.8pp | 69.3%+38.3pp | 31%— | —— | |
| Efficiency | |||||
| Asset turnover | 2.7×0.0× | 2.8×0.0× | 2.8×+0.2× | 2.6×+0.1× | |
| Liquidity | |||||
| Current ratio | 13.1×-1.4× | 14.5×+3.2× | 11.2×-1.5× | 12.8×-6.6× | |
| Leverage | |||||
| Debt-to-equity | 0.7×+0.1× | 0.6×0.0× | 0.6×0.0× | 0.5×+0.1× | |
| Net debt / EBITDA | 0.8×+0.2× | 0.6×-0.7× | 1.2×— | —— | |
| Per Share | |||||
| Book value per share | $112.46+14.5% | $98.22+26.3% | $77.74+25.4% | $62.01+16.6% | |
| Valuation | |||||
| Market capitalization | $51.78B-2.2% | $52.94B+22.9% | $43.09B+8.0% | $39.89B+11.9% | |
| Price / earnings | 134.6×-13.8× | 148.3×-168× | 316.3×-504× | 820.6×+669× | |
| Price / sales | 19.8×-4.7× | 24.5×-0.3× | 24.7×-4.9× | 29.6×-3.8× | |
| Price / book | 18×-2.8× | 20.9×-1.3× | 22.2×-4.1× | 26.3×-1.2× | |
| EV / EBITDA | 91.9×-3.8× | 95.7×-123× | 218.9×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Neurocrine Biosciences's profit margins?
- Neurocrine Biosciences (NBIX) runs a 98.2% gross margin and a 25.4% operating margin, with a 21.6% net margin.
- Where do Neurocrine Biosciences's ratios come from?
- Every ratio is computed from Neurocrine Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
